[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:inborn-error-of-immunity":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":181,"states":182},"Inborn Error of Immunity",28,24,[8,16,22,28,35,41,48,54,60,66,72,78,84,90,96,102,108,113,119,125,131,137,143,149,155,162,168,175],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03266640","Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:31.714843Z","2026-05-05T02:47:14.270391Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03266627","Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection",[12],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.200923Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT03266653","EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection",[12],"2026-08-26T02:15:28.524219Z","2026-05-05T02:43:28.820567Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT04197596","Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)",[32],"Phase 1\u002FPhase 2","2026-08-26T02:18:07.037408Z","2026-05-05T02:43:27.312623Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06990529","Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation",[12],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:26.683206Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT04691622","Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts",[45],"Phase 1","2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.626595Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT04414046","TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children",[12],"2026-08-26T02:15:02.712396Z","2026-04-29T02:57:57.176715Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT04232085","Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures",[12],"2026-08-26T02:17:27.435233Z","2026-05-05T02:43:29.709262Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT02579967","Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies",[12],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.958949Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06909110","Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity",[32],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:27.099634Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT01962415","Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",[12],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:26.722922Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT00001467","Genetic Analysis of Immune Disorders",[],"2026-08-26T02:17:05.997056Z","2026-07-19T19:36:05.116913Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT03610802","Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies",[],"2026-08-26T02:17:28.381459Z","2026-05-13T02:55:06.173931Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT01222741","Studies of Disorders With Increased Susceptibility to Fungal Infections",[],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.070845Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT01011712","The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise",[],"2026-08-26T02:17:09.131534Z","2026-05-13T02:55:06.066321Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT00246857","Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death",[],"2026-08-26T02:15:04.877798Z","2026-07-24T01:27:14.923700Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":39,"content_modified":112},"NCT00001405","Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes",[],"2026-07-05T18:42:10.721265Z",{"nct_id":114,"title":115,"phases":116,"status":13,"updated_at":117,"content_modified":118},"NCT04864886","Metabolic Profiling of Immune Responses in Immune-mediated Diseases",[],"2026-08-26T02:15:59.318403Z","2026-05-13T02:55:06.272434Z",{"nct_id":120,"title":121,"phases":122,"status":13,"updated_at":123,"content_modified":124},"NCT02257892","Novel Genetic Disorders of the Immune System",[],"2026-08-26T02:17:22.949982Z","2026-05-13T02:55:06.091156Z",{"nct_id":126,"title":127,"phases":128,"status":13,"updated_at":129,"content_modified":130},"NCT00404560","Detection and Characterization of Infections and Infection Susceptibility",[],"2026-08-26T02:19:01.741747Z","2026-05-13T02:55:06.039478Z",{"nct_id":132,"title":133,"phases":134,"status":13,"updated_at":135,"content_modified":136},"NCT06169150","Detection and Characterization of Neurologic Manifestations of Inborn and Acquired Errors of Immunity",[],"2026-08-26T02:16:49.565137Z","2026-05-13T02:55:06.423655Z",{"nct_id":138,"title":139,"phases":140,"status":13,"updated_at":141,"content_modified":142},"NCT04784364","Biologics And Clinical Immunology Cohort at Sinai",[],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.268652Z",{"nct_id":144,"title":145,"phases":146,"status":13,"updated_at":147,"content_modified":148},"NCT03394053","The Mechanistic Biology of Primary Immunodeficiency Disorders",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.125193Z",{"nct_id":150,"title":151,"phases":152,"status":13,"updated_at":153,"content_modified":154},"NCT03206099","NIAID Centralized Sequencing Protocol",[],"2026-08-26T02:15:23.202838Z","2026-05-13T02:55:06.109656Z",{"nct_id":156,"title":157,"phases":158,"status":159,"updated_at":160,"content_modified":161},"NCT07670156","Upadacitinib in Treatment of JAK\u002FSTAT Pathway Disorders With Activating Mutations",[32],"NOT_YET_RECRUITING","2026-08-26T02:18:16.220328Z","2026-07-05T03:45:20.371272Z",{"nct_id":163,"title":164,"phases":165,"status":159,"updated_at":166,"content_modified":167},"NCT07660783","Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases",[12],"2026-08-26T02:17:16.980188Z","2026-07-05T03:45:20.258362Z",{"nct_id":169,"title":170,"phases":171,"status":172,"updated_at":173,"content_modified":174},"NCT01852370","Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases",[32],"ENROLLING_BY_INVITATION","2026-08-26T02:17:44.240289Z","2026-06-16T05:54:07.951235Z",{"nct_id":176,"title":177,"phases":178,"status":172,"updated_at":179,"content_modified":180},"NCT00895271","Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders",[],"2026-08-26T02:15:24.145250Z","2026-06-16T05:54:07.944781Z",[],[183,187,191,194,198,201,205,208],{"state":184,"count":185,"slug":186},"Maryland",21,"maryland",{"state":188,"count":189,"slug":190},"New York",6,"new-york",{"state":192,"count":189,"slug":193},"Pennsylvania","pennsylvania",{"state":195,"count":196,"slug":197},"California",5,"california",{"state":199,"count":196,"slug":200},"Missouri","missouri",{"state":202,"count":203,"slug":204},"Ohio",4,"ohio",{"state":206,"count":203,"slug":207},"Wisconsin","wisconsin",{"state":209,"count":210,"slug":211},"District of Columbia",3,"district-of-columbia"]